Nav: Home

Automation speeds clinical safety surveillance

January 25, 2017

Using patient outcomes data from approximately 1,800 hospitals, the largest demonstration to date of automated safety surveillance of a medical device is reported in this week's New England Journal of Medicine.

Vanderbilt medical informatics researcher and internal medicine specialist Michael Matheny, M.D., MPH, M.S., and colleagues demonstrate the effectiveness of an automated web-based surveillance system for spotting potential safety problems with less delay.

Their demonstration concerns a device used to close the small hole left in an artery after the insertion and removal of flexible tubing, that is, the hole left after vascular catheterization.

After three quarterly data uploads from the National Cardiovascular Data Repository CathPCI Registry, the automated system found a statistical signal indicating a potential safety issue with a vascular closure device called the Mynx.

The study's final results were based on data from approximately 146,000 registry patients, half of whom got the Mynx.

"The takeaway is we were able to detect a safety signal fairly quickly. When it comes to post-market safety surveillance for medical devices, you have to be really timely in your safety alerting for it to matter. In our world, nine months is quick enough that if you could get the signal to the FDA, they could act on it," said Matheny, assistant professor of Biomedical Informatics, Medicine and Biostatistics.

Matheny developed the surveillance system in partnership with medical informatics researcher and cardiologist Frederic Resnic, M.D., of Lahey Clinic in Burlington, Massachusetts. They call it DELTA, short for Data Extraction and Longitudinal Trend Analysis.

DELTA performs automated safety analyses and comparative effectiveness studies prospectively, as patient outcomes are electronically documented and uploaded to the system. When DELTA finds potential safety issues, it sends alerts to users via email.

DELTA is freely available as open-source software. According to Matheny, it can be adapted for surveillance of medical devices and drugs, and for quality profiling of clinical services and individual clinicians.

For medical device surveillance the FDA currently relies on case-by-case reports of adverse patient events from health care facilities, health care professionals, patients and manufacturers.

Matheny explained that a medical device company may begin altering a product within two or three years of introducing it, and if there's much of a lag in reporting safety issues, the manufacturer may be able to claim that findings don't apply to the product as it's currently configured.

"DELTA is for a user who understands statistics but isn't necessarily a programmer, who can take the tool box and collaborate with a clinician to design surveillance or comparative effectiveness studies," Matheny said.

For a given project, the user defines the exposures of interest, such as medical devices or drug exposures, and defines patient outcomes and risk factors relative to those exposures.

"Then you set up a time period for surveillance and hit a button. Automatically in the background the system takes the data feeds you've specified and does the sequential analysis, adjusting for repeated measurements, presenting visualizations as patterns emerge.

"If it were just one study, all of that wouldn't be a big deal," Matheny said, "but with DELTA you can clone these analyses, substituting different outcomes, different exposures. You can have 10, 20, 50 different studies running concurrently, and if any one of them finds a safety signal the system sends you an email."

In the study, having eventually captured 34 months of catheterization data, the investigators report that the risk of a vascular complication with the Mynx was 1.21 percent, compared to 0.76 percent with other vascular closure devices used in patients with similar profiles to those who got the Mynx; that is, in similar patients, the risk of a vascular complication was 59 percent greater with the Mynx.

Risk of bleeding at the access site was 0.38 percent with the Mynx, which amounted to a 36 percent increased risk compared to alternative devices.

The Mynx is still on the market.

"We do expect that use of the Mynx will decline. Our study would suggest that, all things being equal, you would use a different device, because of the risk of bleeding," Matheny said.
The investigators received funding from the FDA, the William M. Wood Foundation and the Department of Veterans Affairs.

Vanderbilt University Medical Center

Related Medical Devices Articles:

Graphite nanoplatelets on medical devices kill bacteria and prevent infections
Graphite nanoplatelets integrated into plastic medical surfaces can prevent infections, killing 99.99 per cent of bacteria which try to attach -- a cheap and viable potential solution to a problem which affects millions, costs huge amounts of time and money, and accelerates antibiotic resistance.
Predicting the degradation behavior of advanced medical devices
Polymer materials play a vital role in today's medicine. While many applications demand for long-lasting devices, others benefit from materials that disintegrate once their job is done.
Ingestible medical devices can be broken down with light
MIT engineers have developed a light-sensitive material that allows gastrointestinal devices to be triggered to break down inside the body when they are exposed to light from an ingestible LED.
Fighting bacterial infection with drug-eluting medical devices
Medical practitioners routinely outfit patients with devices ranging from cardiovascular stents, pacemakers, catheters, and therapeutic lenses to orthopedic, breast, dental, and cochlear implants and prostheses.
Concerns over regulation of oral powders or gels sold as medical devices in Europe
Oral powders or gels, sold as medical devices in the European Union (EU), aren't regulated to the same safety standards as those applied to medicines, reveals research published online in the Archives of Disease in Childhood.
Cotton-based hybrid biofuel cell could power implantable medical devices
A glucose-powered biofuel cell that uses electrodes made from cotton fiber could someday help power implantable medical devices such as pacemakers and sensors.
How unsecured medical record systems and medical devices put patient lives at risk
A team of physicians and computer scientists at the University of California has shown it is easy to modify medical test results remotely by attacking the connection between hospital laboratory devices and medical record systems.
Wearable devices: Useful medical insights or just more data?
Despite the popularity of wearable devices to track and measure health and sports performance, a new review highlights how surprisingly little we know we know about how well these sensors and machines work -- let alone whether they deliver useful information.
Hospital superbug uses tiny sticky fingers to infect medical tools and devices
The antibiotic-resistant Acinetobacter baumannii bacterium is one of the most globally harmful bacteria that causes nosocomial infections.
Repetition key to self-healing, flexible medical devices
Medical devices powered by synthetic proteins created from repeated sequences of proteins may be possible, according to materials science and biotechnology experts, who looked at material inspired by the proteins in squid ring teeth.
More Medical Devices News and Medical Devices Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at